C Diff Drug Development

Pfizer recently convened experts representing a cross-section of healthcare professionals and patient organizations for a panel titled, “Clostridioides difficile: A public health threat in plain sight.” They first met during a panel discussion that coincided with Infectious Disease (ID) Week in late-2019 and served as a launchpad for the C.

A toxoid-based Clostridioides difficile vaccine is currently in development. Here, we report lot-to-lot consistency, immunogenicity, safety, and toler…

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stems from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical …

Bacterial infections are characterized by an inflammatory response, which is essential for infection containment but is also responsible for negative effects on the host. The pathogen itself may have evolved molecular mechanisms to antagonize the antimicrobial effects of an inflammatory response and …

Prevention of Clostridium difficile infection is challenging worldwide owing to its high morbidity and mortality rates. C. difficile is currently being classified as an urgent threat by the CDC. Devising a new therapeutic strategy become indispensable against C. difficile infection due to its high r …

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Editorial: An anti-inflammatory approach to drug repurposing for Clostridioides difficile infection

Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients.

Acurx has announced positive results from its Phase IIb clinical trial comparing ibezapolstat to vancomycin in the treatment of CDI.

Acurx (ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. Read more here.

CPX-351, a liposomal combination of cytarabine plus daunorubicin, has been approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes as it improves survival and outcome of haematopoietic stem cell transplante …

The results of the present study for the first time demonstrate the antimicrobial activity and protective effects of A. millefolium extracts on inflammatory response and apoptosis induced by Tox-S from C. difficile RT001 clinical strain in vitro. Further research is needed to evaluate the potential …

Therapy for Clostridioides difficile infections includes the use of antibiotics, immunosuppressors, and fecal microbiota transplantation. However, these treatments have several drawbacks, including the loss of colonization resistance, the promotion of autoimmune disorders, and the potential f …

Clostridioides difficile remains a major public health threat, and new approaches are needed to develop an effective vaccine. To date, the industry has focused on intramuscular vaccination targeting the C. difficile toxins. Multiple disappointing results in phase III trials have largel …

In a phase-one human clinical trial, a University of Houston pharmacist researcher has demonstrated that a newer generation tetracycline antibiotic, called Omadacycline, may be a promising tool in combating ...

Phase 1 trial shows new RX Fights C Diff and spares healthy microbiota.

With the aim of discovering small molecule inhibitors of the sporulation process in Clostridioides difficile, we prepared a series of C-7 α-(4-substituted-1H-1,2,3-triazol-1-yl)acetamide analogues of cefotetan, a known inhibitor of the C. difficile sporulation-specific protein t …

The Business Research Company's Difficile-Associated Diarrhea Treatment Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

Hospitals considering probiotics as a primary prevention strategy should consider the baseline incidence of HA-CDI in their population and timing of probiotics relative to the start of antimicrobial administration.

Distiller's grains, byproducts of the brewing process, represent a valuable resource for extracting natural phenolic compounds due to their significant global production. This study presents the first evidence of the protective effects of Moutai distiller's grain polyphenol extract (MDGP) on dextran …

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced efficacy results from the Phase 2 clinical trial (Phase 2a segment and Phase 2b segment) of ibezapolstat for the treatment of C. difficile Infection (CDI).

The first part of this contribution describes solutions that were developed to achieve progressively more efficient syntheses of the thiopeptide natural products, micrococcins P1 and P2 (MP1-MP2), with an eye toward exploring their potential as a source of new antibiotics. Such efforts enabled inves …

Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the human body to fight disease, is shutting down after running out of cash and viable drug candidates.

Iron storage “spheres” inside C. difficile, the leading cause of hospital-acquired infections, could offer new targets for antibacterial drugs.

Scientific Reports - Bacillus velezensis DSM 33864 reduces Clostridioides difficile colonization without disturbing commensal gut microbiota composition

ClinicalTrials.gov identifier: NCT03579459.